Cargando…
Mathematical modelling of the most effective goal of cholesterol-lowering treatment in primary prevention
OBJECTIVE: To compare quantitatively different recommended goals for cholesterol-lowering treatment in the primary prevention of atherosclerotic cardiovascular disease (ASCVD). DESIGN: Outcomes at pretreatment low-density lipoprotein (LDL) cholesterol concentrations from 2 to 5 mmol/L and 10-year AS...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131112/ https://www.ncbi.nlm.nih.gov/pubmed/35613766 http://dx.doi.org/10.1136/bmjopen-2021-050266 |
_version_ | 1784713116498526208 |
---|---|
author | Soran, Handrean Adam, Safwaan Iqbal, Zohaib Durrington, Paul |
author_facet | Soran, Handrean Adam, Safwaan Iqbal, Zohaib Durrington, Paul |
author_sort | Soran, Handrean |
collection | PubMed |
description | OBJECTIVE: To compare quantitatively different recommended goals for cholesterol-lowering treatment in the primary prevention of atherosclerotic cardiovascular disease (ASCVD). DESIGN: Outcomes at pretreatment low-density lipoprotein (LDL) cholesterol concentrations from 2 to 5 mmol/L and 10-year ASCVD risk from 5% to 30% were modelled, using the decrease in risk ratio per mmol/L reduction in LDL cholesterol derived from randomised controlled trials (RCTs) of cholesterol-lowering medication. DATA SOURCE: Summary statistics from 26 RCTs comparing treatment versus placebo or less versus more effective treatment and 12 RCTs in which statin was compared with a higher dose of the same statin or with a similar statin dose to which an adjunctive cholesterol-lowering drug was added. SETTING: The different recommended goals are: (1) LDL cholesterol≤2.6 mmol/L (100 mg/dL); (2) LDL cholesterol≤1.8 mmol/L (70 mg/dL); (3) non-high density lipoprotein (HDL) cholesterol decrease of ≥40%; or (4) LDL cholesterol≤1.8 mmol/L (70 mg/dL) or decreased by ≥50% whichever is lower. PARTICIPANTS: RCT participants. INTERVENTIONS: Statins alone or in combination with ezetimibe or proprotein convertase subtilisin/kexin type 9 inhibitors. MAIN OUTCOME MEASURES: For each of the recommended therapeutic goals, our primary outcome was the number of events prevented per 100 people treated for 10 years (N(100)) and the number of needed to treat (NNT) to prevent one event over 10 years. RESULTS: At pretreatment LDL cholesterol 4–5 mmol/L, all four goals provided similar benefit with N(100) 1.47–16.45 (NNT 6–68), depending on ASCVD risk and pretreatment LDL cholesterol. With initial LDL cholesterol in the range 2–3 mmol/L, the target of 2.6 mmol/L was the least effective with N(100) between 0 and 2.84 (NNT 35–infinity). The goal of 1.8 mmol/L was little better. However, reductions in non-HDL cholesterol by ≥40% or of LDL cholesterol to 1.8 mmol/L and/or by 50%, whichever is lower, were more effective, delivering N(100) of between 0.9 and 9.33 (NNT 11–111). Percentage decreases in LDL cholesterol or non-HDL cholesterol concentration are more effective targets than absolute change in concentration in people with initial values of <4 mmol/L. CONCLUSIONS: The LDL cholesterol target of 1.8 mmol/L is most effective when initial LDL cholesterol is >4 mmol/L. The time has probably come for the LDL cholesterol goal of <2.6 mmol/L to be abandoned. |
format | Online Article Text |
id | pubmed-9131112 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-91311122022-06-09 Mathematical modelling of the most effective goal of cholesterol-lowering treatment in primary prevention Soran, Handrean Adam, Safwaan Iqbal, Zohaib Durrington, Paul BMJ Open Diabetes and Endocrinology OBJECTIVE: To compare quantitatively different recommended goals for cholesterol-lowering treatment in the primary prevention of atherosclerotic cardiovascular disease (ASCVD). DESIGN: Outcomes at pretreatment low-density lipoprotein (LDL) cholesterol concentrations from 2 to 5 mmol/L and 10-year ASCVD risk from 5% to 30% were modelled, using the decrease in risk ratio per mmol/L reduction in LDL cholesterol derived from randomised controlled trials (RCTs) of cholesterol-lowering medication. DATA SOURCE: Summary statistics from 26 RCTs comparing treatment versus placebo or less versus more effective treatment and 12 RCTs in which statin was compared with a higher dose of the same statin or with a similar statin dose to which an adjunctive cholesterol-lowering drug was added. SETTING: The different recommended goals are: (1) LDL cholesterol≤2.6 mmol/L (100 mg/dL); (2) LDL cholesterol≤1.8 mmol/L (70 mg/dL); (3) non-high density lipoprotein (HDL) cholesterol decrease of ≥40%; or (4) LDL cholesterol≤1.8 mmol/L (70 mg/dL) or decreased by ≥50% whichever is lower. PARTICIPANTS: RCT participants. INTERVENTIONS: Statins alone or in combination with ezetimibe or proprotein convertase subtilisin/kexin type 9 inhibitors. MAIN OUTCOME MEASURES: For each of the recommended therapeutic goals, our primary outcome was the number of events prevented per 100 people treated for 10 years (N(100)) and the number of needed to treat (NNT) to prevent one event over 10 years. RESULTS: At pretreatment LDL cholesterol 4–5 mmol/L, all four goals provided similar benefit with N(100) 1.47–16.45 (NNT 6–68), depending on ASCVD risk and pretreatment LDL cholesterol. With initial LDL cholesterol in the range 2–3 mmol/L, the target of 2.6 mmol/L was the least effective with N(100) between 0 and 2.84 (NNT 35–infinity). The goal of 1.8 mmol/L was little better. However, reductions in non-HDL cholesterol by ≥40% or of LDL cholesterol to 1.8 mmol/L and/or by 50%, whichever is lower, were more effective, delivering N(100) of between 0.9 and 9.33 (NNT 11–111). Percentage decreases in LDL cholesterol or non-HDL cholesterol concentration are more effective targets than absolute change in concentration in people with initial values of <4 mmol/L. CONCLUSIONS: The LDL cholesterol target of 1.8 mmol/L is most effective when initial LDL cholesterol is >4 mmol/L. The time has probably come for the LDL cholesterol goal of <2.6 mmol/L to be abandoned. BMJ Publishing Group 2022-05-23 /pmc/articles/PMC9131112/ /pubmed/35613766 http://dx.doi.org/10.1136/bmjopen-2021-050266 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Diabetes and Endocrinology Soran, Handrean Adam, Safwaan Iqbal, Zohaib Durrington, Paul Mathematical modelling of the most effective goal of cholesterol-lowering treatment in primary prevention |
title | Mathematical modelling of the most effective goal of cholesterol-lowering treatment in primary prevention |
title_full | Mathematical modelling of the most effective goal of cholesterol-lowering treatment in primary prevention |
title_fullStr | Mathematical modelling of the most effective goal of cholesterol-lowering treatment in primary prevention |
title_full_unstemmed | Mathematical modelling of the most effective goal of cholesterol-lowering treatment in primary prevention |
title_short | Mathematical modelling of the most effective goal of cholesterol-lowering treatment in primary prevention |
title_sort | mathematical modelling of the most effective goal of cholesterol-lowering treatment in primary prevention |
topic | Diabetes and Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131112/ https://www.ncbi.nlm.nih.gov/pubmed/35613766 http://dx.doi.org/10.1136/bmjopen-2021-050266 |
work_keys_str_mv | AT soranhandrean mathematicalmodellingofthemosteffectivegoalofcholesterolloweringtreatmentinprimaryprevention AT adamsafwaan mathematicalmodellingofthemosteffectivegoalofcholesterolloweringtreatmentinprimaryprevention AT iqbalzohaib mathematicalmodellingofthemosteffectivegoalofcholesterolloweringtreatmentinprimaryprevention AT durringtonpaul mathematicalmodellingofthemosteffectivegoalofcholesterolloweringtreatmentinprimaryprevention |